DERM (Journey Medical) Tariff Resilience Score: 5/10 (As of Jun. 28, 2026)


DERM Journey Medical Corp DERM
63 GF Score
Price $6.62
GF Value $4.17
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Journey Medical Tariff Resilience Score?

Journey Medical DERM +6.43% 63 Tariff Resilience Score is 5 as of Jun. 28, 2026. GuruFocus rates DERM with a GF Score™ of 63/100 and a GF Value™ of $4.17 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 1,028 Drug Manufacturers companies, Journey Medical ranks better than 84.63% on this metric.

Journey Medical has the Tariff Resilience Score of 5, which implies that the company might have Average Resilient.

Journey Medical has Journey Medical's exposure to tariffs is moderate due to its reliance on international suppliers for raw materials. However, its focus on the U.S. market and potential for alternative sourcing provide some resilience.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Journey Medical might have Average Resilient.

Journey Medical  (NAS:DERM) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Journey Medical Tariff Resilience Score Related Terms

DERM vs LFCR, ANIK, ASRT: Tariff Resilience Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Journey Medical's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Journey Medical Tariff Resilience Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Journey Medical's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Journey Medical's Tariff Resilience Score falls into.


DERM
63GF Score
Journey Medical Corp DERM
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 5 mean?
Journey Medical (DERM) has a Tariff Resilience Score of 5 as of Jun. 28, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Journey Medical ranks #158 out of 1028 companies in the Drug Manufacturers industry, placing it in the top 15.4%.
Is Journey Medical's Tariff Resilience Score too high?
Journey Medical's current Tariff Resilience Score is 5. Based on the distribution chart, Journey Medical ranks #158 out of 1028 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Journey Medical has a GF Score™ of 63/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Journey Medical's Tariff Resilience Score compare to LFCR and ANIK?
According to the Drug Manufacturers industry distribution chart, Journey Medical ranks #158 out of 1028 companies for Tariff Resilience Score. This places Journey Medical in the top 15% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Drug Manufacturers company?
A good Tariff Resilience Score depends on the Drug Manufacturers industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. Journey Medical's current Tariff Resilience Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Journey Medical stock overvalued right now?
Based on GuruFocus' analysis, Journey Medical (DERM) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.17, compared to a current price of $6.62 — trading 58.8% above its estimated fair value. The current Tariff Resilience Score is 5. Journey Medical's overall GF Score™ is 63/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Journey Medical (DERM), the current Tariff Resilience Score is 5 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Journey Medical (DERM) Overvalued in 2026?

Based on GuruFocus' analysis, Journey Medical stock appears to be overvalued. The current stock price of $6.62 is trading 58.8% above its estimated GF Value™ of $4.17. GuruFocus considers Journey Medical to be Significantly Overvalued.

Key valuation signals for DERM:

  • Tariff Resilience Score: 5
  • GF Value™: $4.17 vs. price of $6.62 (58.8% above fair value)
  • GF Score™: 63/100 with 3 warning signs

No single metric tells the full story. See the DERM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Journey Medical Business Description

Address 9237 E Via de Ventura Boulevard, Suite 105, Scottsdale, AZ, USA, 85258
Journey Medical Corp is a commercial-stage pharmaceutical company that focuses on the selling and marketing of U.S. Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its current product portfolio includes FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. The company views its operations and manages its business in one segment, which reflects products for the treatment of dermatological conditions. The dermatological segment derives revenues from the sale of branded and authorized general prescription products that treat certain dermatological conditions.
63GF Score

Get the complete analysis for DERM

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.62
Price
$4.17
GF Value